赛诺菲任命默克KGaA的贝伦·加里约为新首席执行官,自2026年4月29日起,继任保罗·哈德森. Sanofi names Merck KGaA’s Belén Garijo as new CEO, effective April 29, 2026, succeeding Paul Hudson.

赛诺菲任命了目前的默克KGaA首席执行官贝伦·加里约为其新首席执行官,该职位将于2026年4月29日的年度会议后生效,接替了立即辞职而没有公开解释的保罗·哈德森. Sanofi has named Belén Garijo, currently CEO of Merck KGaA, as its new CEO, effective after its April 29, 2026, annual meeting, succeeding Paul Hudson, who stepped down immediately without a public explanation. 哈德森自2019年以来一直领导赛诺菲,尽管在2025年销售额增长了6.2%,但他因药物开发停滞和股价下跌25%而面临批评. Hudson, who led Sanofi since 2019, faced criticism over stalled drug development and a 25% drop in stock value, despite a 6.2% sales increase in 2025. Garijo是前Sanofi执行官,在该公司有15年经验,将着重提高研发生产力、执行和创新。 Garijo, a former Sanofi executive with 15 years of experience at the company, will focus on improving R&D productivity, execution, and innovation. Olivier Charmeil将担任临时首席执行官,直到Garijo正式任命为止。 Olivier Charmeil will serve as interim CEO until Garijo’s formal appointment.